A randomized phase III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for participants with painful non-spine bone metastases (NCT06391242).
TPS12141 Background: Stereotactic body radiotherapy (SBRT) is efficacious in the treatment of painful spinal metastases [1]. Data are required regarding the efficacy feasibility, toxicity and clinical outcomes associated with SBRT in patients with painful non-spine bone metastases prior to widespread adoption of this technique. Methods: This is a Canadian Cancer Trials Group led multi-centre, phase III randomized controlled trial comparing SBRT to conventional palliative external beam radiotherapy (CRT) in patients with solid tumours and a dominant painful non-spine bone metastasis (worst pain score >2). Treatment arms: EBRT 20Gy/5fr (control) versus SBRT 35 Gy/5fr or 30Gy/5fr (experimental). Primary objective : To compare 3-month complete pain response (CPR) rate and analgesic intake assessed using the International Consensus on Palliative Radiotherapy Endpoints [2]. Secondary objectives evaluate pain response pattern at 1, 3 and 6 months and assess re-irradiation rates, fracture incidence within RT target site, incidence of Grade > 2 adverse events, image-based local control, and patient reported outcomes (EORTC QLQ-C30 and QLQ-BM22). Statistical design: The target accrual is 230 patients, randomized 1:1. The trial is powered at 80% with a two-sided alpha of 0.05 to detect an improvement in the CPR rate from 17% (CRT) to 34% (SBRT), accounting for a 15% missing data rate. Conduct to Date : Study was activated on June 26, 2024. Supported by CCS grant # 707213. [1] Sahgal, Arjun, et al. "Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial." The Lancet Oncology 22.7 (2021): 1023-1033. [2] Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, Hartsell W, Kumar E; International Bone Metastases Consensus Working Party. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1730-7. doi: 10.1016/j.ijrobp.2011.02.008. Epub 2011 Apr 12. PMID: 21489705. Clinical trial information: NCT06391242 .
Authors
- Anand Swaminath (ORCID: https://orcid.org/0000-0003-4013-1980)
- Arjun Sahgal (ORCID: https://orcid.org/0000-0001-7991-8970)
- Pejman Maralani (ORCID: https://orcid.org/0000-0001-9975-4379)
- Tim Nguyen
- Marc Kerba (ORCID: https://orcid.org/0000-0002-2615-3019)
- Kristopher Dennis (ORCID: https://orcid.org/0000-0002-5588-1007)
- Joël Lefebvre (ORCID: https://orcid.org/0000-0002-6652-2130)
- Wendy R. Parulekar (ORCID: https://orcid.org/0000-0002-6007-7494)
- C. Jillian Tsai (ORCID: https://orcid.org/0009-0004-8051-0787)
- Isabelle Thibault (ORCID: https://orcid.org/0000-0002-2161-2124)
- Michael Brundage (ORCID: https://orcid.org/0000-0002-5104-0497)
- Wei Tu (ORCID: https://orcid.org/0000-0001-7031-9189)
- Laura Masucci
- Emma Dunne
Institutions
- BC Cancer Agency (CA)
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- Queen's University (CA)
- Juravinski Cancer Centre (CA)
- Ottawa Hospital (CA)
- London Health Sciences Centre (CA)
- Health Sciences Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Université Laval (CA)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1200/jco.2025.43.16_suppl.tps12141
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00